Gelonghui, January 12 | Kehua Biotech (002022.SZ) said on the investor interactive platform that the company's main business is R&D, production and sales of in vitro diagnostic reagents and medical testing instruments. The company will continue to pay attention to industry trends and market needs, and pay close attention to the development and application of cutting-edge technology, choose upgrade methods that meet user needs and the company's development direction according to different product attributes to continuously improve user experience and product performance.
科华生物(002022.SZ)：主营业务为体外诊断试剂、医疗检验仪器的研发、生产和销售
Kehua Biology (002022.SZ): Main business is R&D, production and sales of in vitro diagnostic reagents and medical testing instruments
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.